Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours
2011

cPLA2-α and Breast Cancer Prognosis

Sample size: 18 publication 10 minutes Evidence: moderate

Author Information

Author(s): Caiazza F, McCarthy N S, Young L, Hill A D K, Harvey B J, Thomas W

Primary Institution: Royal College of Surgeons in Ireland

Hypothesis

cPLA2α activity and expression could be correlated with HER2-overexpressing tumours.

Conclusion

cPLA2α expression is associated with poor prognosis in luminal breast cancer and may serve as a predictive marker for treatment response.

Supporting Evidence

  • High cPLA2α mRNA expression correlated with clinical parameters of poor prognosis.
  • Patients with high cPLA2α expression had a reduced overall survival compared to those with low expression.
  • cPLA2α expression was an independent predictive parameter of poor response to endocrine therapy.

Takeaway

This study found that a protein called cPLA2α is linked to worse outcomes in some breast cancer patients, especially those with certain types of tumors.

Methodology

The study analyzed cPLA2α expression in tissue samples from breast cancer patients using quantitative real-time PCR and gene expression microarrays.

Potential Biases

Potential bias due to the selection of patients and the methods used for determining HER2 status.

Limitations

The study's findings may not be generalizable due to the small sample size and specific patient population.

Participant Demographics

18 breast cancer patients, 15 ER positive and 3 ER negative.

Statistical Information

P-Value

p<0.01

Confidence Interval

95% CI: 0.069–0.862

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6606025

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication